INTERLEUKIN-2 AND THE TREATMENT OF LEUKEMIA AND LYMPHOMA

被引：4

作者：

BRENNER, MK

机构：

[1] Division of Bone Marrow Transplantation, Department of Hematology/Oncology, St. Jude Children's Research Hospital and Departments of Pediatrics and Medicine, University of Tennessee College of Medicine, Memphis, TN

来源：

LEUKEMIA & LYMPHOMA | 1991年 / 5卷 / 2-3期

基金：

美国国家卫生研究院;

关键词：

INTERLEUKIN-2; IL-2; TREATMENT; LEUKEMIA AND LYMPHOMA;

D O I：

10.3109/10428199109068109

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As evidence has accumulated that allogeneic bone marrow transplantation provides therapeutic benefit by means of a graft versus malignancy effect, there has been a corresponding increase in interest in inducing or enhancing such an effect after chemotherapy and/or autologous bone marrow transplantation. Administration of Interleukin-2 may be one way of achieving this aim. Recent studies have shown the cytokine is tolerated after ABMT/chemotherapy in immunomodulatory doses and that the MHC unrestricted cytotoxic effector mechanisms induced can indeed discriminate between normal and malignant tissue. As always, larger scale randomized studies will be required before the therapeutic efficacy of this approach can been assessed. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：77 / 83

页数：7

共 36 条

[1]

Lotzova E., Savary C.A., Herberman R.B., Induction of NK cell activity against fresh human leukemia in culture with interleukin 2, J. Immunol, 138, (1987)

[2]

Kasahara T., Hooks J.J., Dougherty S.F., Oppenheim J.J., Interleukin 2 mediated immune interferon (IFN-gamma) production by human T cell and T cell subsets, J. Immunol, 130, (1983)

[3]

Heslop H.E., Gottlieb D.J., Bianchi A.C.M., Meager A., Prentice H.G., Mehta A.B., Hoffbrand A.V., Brenner M.K., In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation, Blood, 74, (1989)

[4]

Gottleib D.J., Brenner M.K., Heslop H.E., Bello-Fernandez C., Galazka A., Prentice H.G., Effects of recombinant interleukin 2 administration on cytotoxic function following high dose chemoradiotherapy for haematologic malignancy, Blood, 74, (1989)

[5]

Broxmeyer H.E., Williams D.E., Lu L., Cooper S., Anderson S.L., Beyer G.S., Hoffman R., Rubin Y.Y., The suppressive influences of human tumor necrosis factor on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: Synergism of tumour necrosis factor and interferon-gamma, J. Immunol, 136, (1986)

[6]

Price G., Brenner M.K., Prentice H.G., Hoffbrand A.V., Newland A.C., Cytotoxic effects of tumour necrosis factor and gamma interferon on acute myeloid leukaemia blast cells, Br. J. Cancer, 55, (1987)

[7]

Murphy M., Loudon R., Kobayashi M., Trinchieri G., y interferon and lymphotoxin, released by activated T cells, synergize to inhibit granulocyte/monocyte colony formation, J. Exp. Med, 164, pp. 263-279, (1986)

[8]

Peetre G., Gullberg U., Nilsson E., Olsson I., Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hemopoietic cells in vitro, J. Clin. Invest, 78, pp. 1694-1700, (1986)

[9]

Murase T., Hotta T., Saito H., Ohno R., Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells, Blood, 69, pp. 467-472, (1987)

[10]

Munker R., Koeffler P., In vitro action of tumor necrosis factor of myeloid leukemia cells, Blood, 69, pp. 1102-1108, (1987)

← 1 2 3 4 →